🎧 Podcast episode for paid subscribers only. Also available on Apple Podcasts and Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of contents
The two billion dollar number needs an accountant
Eroom’s Law survives better tools
Where AI has earned some credit
Clinical trials are where the spreadsheet meets a person
Formation Bio is buying development capacity
The financing structure deserves its own diligence
What investors should actually measure
Cheaper development could change which diseases get drugs
Abstract
AI can generate plausible molecules much faster than the pharmaceutical industry can establish whether those molecules deserve to become medicines. That mismatch explains both the excitement around computational discovery and the growing interest in companies that finance and operate clinical development. Evidence already supports gains in molecular modeling, patient screening, and certain measurement tasks. Evidence for a durable improvement in approval rates is much less mature. Formation Bio’s six hundred million dollar Drug Development Accelerator Fund offers a useful way to examine the business opportunity: acquire or in-license clinical assets, share operating infrastructure, and finance programs through meaningful readouts. The investment case depends on better decisions, lower development costs, and disciplined ownership economics. A faster molecular suggestion box will not get the whole job done.


